



Press release
October 27, 2016
Gothenburg

Two LS™ contract signed in Spain

The two LS™ are the first EVLP machines to be sold to Spain and the first LS™ to be sold by XVIVO Perfusion. Delivery and installation of the LS™ will take place in Q4 2016.

The Hospital Universitario Marques de Valdecilla, Santander, has decided to start an EVLP program and the installation is planned to Q4, 2016. The investment was made thank to a grant from Fundacion Marques de Valdecilla.

Hospital Universitario Reina Sofia, Cordoba and IMIBIC (Maimonides Institute for Biomedical Research of Córdoba) were granted by Fundacion Mutua Madrileña.

“We are delighted and proud that EVLP with LS™ and STEEN Solution™ will be used for evaluating lungs for transplantation in Spain. The two LS™ are the first to be sold by XVIVO Perfusion and Spain is a new country with an EVLP machine. The company sees a continued high interest from American and European clinics to setup machine perfusion to facilitate lung evaluation with the aim of using more of the donated lungs”, says Magnus Nilsson, CEO of XVIVO Perfusion.

October 27, 2016
Gothenburg
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, tel: +1 720 616 2101, email: christoffer.rosenblad@xvivoperfusion.com

Magnus Nilsson, CEO, tel +46 31 788 2150, email: magnus.nilsson@xvivoperfusion.com

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.

The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on Nasdaq First North Premier and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.

Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.

E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 7:30 a.m. CET on October 27, 2016.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.